Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanosonics Limited ( (AU:NAN) ) has provided an announcement.
UBS Group AG and its related bodies corporate have notified Nanosonics Limited that they have ceased to be a substantial shareholder in the company as of 15 April 2026. The change reflects a reduction in UBS’s relevant voting interests below the substantial holding threshold, potentially altering Nanosonics’ institutional investor base and the distribution of its share register, although no new associates or address changes were disclosed.
The notice indicates that UBS had previously reported its substantial holding status only days earlier, underscoring a relatively rapid shift in its position. While the filing does not specify the detailed transaction data contained in the appendix, the exit of a major holder may influence market perceptions of Nanosonics’ stock and could prompt closer scrutiny from other investors regarding liquidity and ownership dynamics.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.55 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited is a medical technology company focused on infection prevention, best known for its ultrasound probe disinfection systems used in hospitals and clinics. The company operates in the healthcare and medical devices sector, supplying specialized equipment that supports clinical safety and regulatory compliance in infection control.
Average Trading Volume: 796,047
Technical Sentiment Signal: Sell
Current Market Cap: A$1.08B
Learn more about NAN stock on TipRanks’ Stock Analysis page.